The Safety of Glucagon use during ERCP in Diabetic Patients with Renal Insufficiency: A Case Discussion and Review of Literature
DOI:
https://doi.org/10.18776/50y5r380Keywords:
Endoscopic retrograde cholangiopancreatography, , Glucagon, ERCP, Diabetes, Diabetic, Renal Insufficiency, Renal insufficiency, HyperkalemiaAbstract
This is a case report with the use of glucagon during ERCP which resulted in Hyperkalemia. A 45 year old male, ASA 3, with Type 1 diabetes mellitus, hypertension, and chronic kidney disease underwent ERCP with general anesthesia for evaluation of a bile duct stricture. After administration of 0.75 mg glucagon (0.25 mg doses over an hour) tall, peaked T-waves were noted on the ECG. Labs were drawn and potassium was 6.6 mEq/L and glucose was 393 mg/dL. Intravenous calcium chloride, 1000 mg, was titrated. Repeat potassium was 6.1mEq/L and glucose 568 mg/dL. The remainder of the procedure was uneventful and postoperative potassium was 5.2 mEq/dL.
References
Endoscopic cannulation of the ampulla of vater: a preliminar report. Mccune, W. S., Shorb, P E and Moscovitz, H. 5, 1968, Ann Surg, Vol. 162, pp. 752-756.
How and when should NSAIDS be used for preventing post ERCP pancreatitis? A systematic review and meta analysis. Puig, Ignasi, et al., et al. 3, Mar 27, 2014, PLOS One, Vol. 9, p. e92922.
Trends in utilization of diagnostic and therapeutic ERCP and cholecystectomy over the past 25 years: a population based study. Moffatt, Dana C, et al., et al. 4, 2014, Gastrointestinal Endoscopy, Vol. 79, pp. 615-622.
Malas, Ahmad and Roberts, Kurt. emedicine.medscape.com. Endoscopic retrograde cholangiopancreatography: Overview, Periprocedural care, Technique. [Online] medscape, May 13, 2015. [Cited: September 12, 2015.]
Endoscopic retrograde cholangiopancreatography (ERCP), Institute for Cancer Genetics and informatics. YouTube, https://youtu.be/IRdA2krJ6LQ, 13 Spetember, 2013. Web. 19 November 2016.
Thomson. Physician desk reference. Montvale: Thomson PDR, 2014.
Pharmacology of the spincter of Oddi. Staritz, M. suppl 1, 1988, Endoscopy, Vol. 20, pp. 171-174.
Glucagon (1-21) peptide. Study of its action on spincter of Oddi function by endoscopic manometry. Rey, J F, Greff, M and Picazo, J. 4, s.l. : Digestive diseases and sciences, April 1986, Vol. 31, pp. 355-360.
Effects of intravenous glucagan (1-21) peptide on motor activity of sphincter of Oddi in humans. Ponce, J, et al., et al. 1, 01 1989, Digestive Diseases & Sciences, Vol. 34, pp. 61-64.
A prospective double blind trial of L-hyoscyamine versus glucagon for the inhibition of small intestinal motility during ERCP. Lahoti, S, et al., et al. 2, 1997, Gastrointestinal Endoscopy, Vol. 46, pp. 139-142.
Evidence for a role of endogenour insulin and glucagon in the regulation of potassium homeostasis. Santeusanio, F, et al., et al. 6, June 1973, The journal of Laboratory and clinical medicine, Vol. 81.
Influence of glucagon on plasm levels of potassium in man. Massara, F, et al., et al. 1980, Diabetologia, Vol. 19, pp. 414-17.
Factors that affect the variability in heart rate during endoscopic retrograde cholangiopancreatography. Christensen, M, et al., et al. 2002, Eur J surg, Vol. 168, pp. 546-51.
Somers MP, Brady W, Perron A, Mattu A. The prominent T wave: electrocardiographic differential diagnosis. Am J Emerg Med 2002; 20:243-51.
Lynch CR, Khandekar S, Lynch SM, Disario JA. Sublingual L-hyoscyamine for duodenal antimotility during ERCP: a prospective randomized double-blinded study. Gastrointest Endosc. 2007 Oct;66(4):748-52.
Downloads
Published
Issue
Section
License
Authors agree to the Creative Commons License listed below, which can be viewed by clicking the link below.
This work will be licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.